Nanexa AB - Home

Where Nanoengineering
Meets Drug Delivery

Nanexa’s PharmaShell® technology is transforming the face of long-acting ’super generic’ drugs with its proprietary suite of Atomic Layer Deposition (ALD) technologies.
PharmaShell formulations will allow indications including type 2 diabetes/obesity, cancers, cardiovascular and psychiatric disorders to be treated with monthly injections.

PRESSRELEASES

10 December, 2025

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.

6 November, 2025

Nanexa publishes interim report for January-September 2025

We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.